Prague Med. Rep. 2015, 116, 112-121

https://doi.org/10.14712/23362936.2015.50

Changes in the Pattern of Primary Hyperparathyroidism in Czech Republic

Petr Broulík1, Svatopluk Adámek2, Petr Libánský2, Jozef Kubinyi3

13rd Department of Medicine – Department of Endocrinology and Metabolism, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic
23rd Department of Surgery, First Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic
3Institute of Nuclear Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic

Received February 16, 2015
Accepted June 1, 2015

References

1. Adami, S., Marcocci, C., Gatti, D. (2002) Epidemiology of primary hyperparathyroidism in Europe. J. Bone Miner. Res. 17, N18–N23.
2. Bolland, M. J., Grey, A. B., Gamble, G. D., Reid, I. R. (2005) Association between primary hyperparahyroidism and increased body weight: a meta analysis. J. Clin. Endocrinol. Metab. 90, 1525–1530. <https://doi.org/10.1210/jc.2004-1891>
3. Broulík, P. D., Horký, K., Pacovský, V. (1985) Blood pressure in patients with primary hyperparathyroidism before and after parathyroidectomy. Exp. Clin. Endocrinol. 86, 346–352. <https://doi.org/10.1055/s-0029-1210507>
4. Broulík, P. D., Horký, K., Pacovský, V. (1986) Effect of parathyroid hormone on plasma renin activity in humans. Horm. Metab. Res. 18, 490–492. <https://doi.org/10.1055/s-2007-1012353>
5. Broulík, P. D., Štěpán, J. J., Pacovský, V. (1987) Primary hyperparathyrodism and hyperuricaemia are associated but not correlated with indicators of bone turnover. Clin. Chim. Acta 170, 195–200. <https://doi.org/10.1016/0009-8981(87)90128-8>
6. Broulík, P. D., Haas, T., Adámek, S. (2003) Further experience with peptic ulcer disease and pancreatitis as a diagnostic clue to primary hyperparathyroidism. Sb. Lek. 104, 247–254.
7. Broulík, P. D., Haas, T., Adámek, S. (2005) Analysis of 645 patients with primary hyperparathyroidism with special reference to cholelithiasis. Intern. Med. 44, 917–921. <https://doi.org/10.2169/internalmedicine.44.917>
8. Broulík, P. D., Broulíková, A., Adámek, S., Libánský, P., Tvrdoň, J., Broulíková, K., Kubinyi, J. (2011) Improvement of hypertension after parathyroidectomy of patients suffering from primary hyperparathyroidism. Int. J. Endocrinol. 2011, 309068, doi:10.1155/2011/309068. <https://doi.org/10.1155/2011/309068> <PubMed>
9. Cífková, R., Škodová, Z., Lánská, V., Adámková, V., Novozámská, E., Petržílková, Z., Jozífková, M., Plášková, M., Hejl, Z., Palouš, D., Galovcová, M. (2004) Trends in blood pressure levels, prevalence, awareness, treatment, and control of hypertension in the Czech population from 1985 to 2000/01. J. Hypertens. 22, 1479–1485.
10. Feig, D. I., Kang, D. H., Johnson, R. J. (2008) Uric acid and cardiovascular risk. N. Engl. J. Med. 359, 1811–1821. <https://doi.org/10.1056/NEJMra0800885> <PubMed>
11. Horký, K., Broulík, P. D., Pacovský, V. (1986) The effect of parathyroid hormone on plasma renin activity in humans and hypertension in patients with primary hyperparathyrodism. J. Hypertens. 4, S585–S587.
12. Jorde, R., Svartberg, J., Sundsfjord, J. (2005) Serum parathyroid hormone as a predictor of increase in systolic blood pressure in men. J. Hypertens. 23, 1639–1644. <https://doi.org/10.1097/01.hjh.0000179764.40701.36>
13. Khaleeli, A. A., Johnson, J. N., Taylor, W. H. (2007) Prevalence of glucose intolerance in primary hyperparathyroidism and the benefit of parathyroidectomy. Diabetes Metab. Res. Rev. 23, 43–48. <https://doi.org/10.1002/dmrr.637>
14. Kiernan, T. J., O’Flynn, A. M., McDermontt, J. H., Kearney, P. (2006) Primary hyperparathyroidism and the cardiovascular system. Int. J. Cardiol. 113, E89–E92. <https://doi.org/10.1016/j.ijcard.2006.05.033>
15. Kubinyi, J., Trnka, J., Adámek, S., Libánský, P., Broulík, P. (2010) Clinical validation of a modified tomographic protocol for preoperative localization of parathyroid glands in patients with hyperparathyroidism based on volume rendering vizualization and 3D substraction. Eur. J. Nucl. Med. Mol. Imaging 37, S203–S204 (Suppl. 2).
16. Marcocci, C., Cetani, F. (2011) Primary hyperparathyroidism. N. Engl. J. Med. 22, 2389–2397. <https://doi.org/10.1056/NEJMcp1106636>
17. Shearer, M. G., Imrie, C. W. (1986) Parathyroid hormone levels, hyperparathyroidism and acute pancreatitis. Br. J. Surg. 73, 282–284. <https://doi.org/10.1002/bjs.1800730412>
18. Silverberg, S. J., Bilezikian, J. P. (2001) Clinical presentation of primary hyperparathyroidism in the United States. In: The Parathyroids, 2nd Edition, eds. Bilezikian, J. P., Marcus, R., Levine, M. A., pp. 349–360, Raven Press, New York.
19. Škrha, J., Šrámková, J., Broulík, P., Páv, J. (1988) Glycoregulation in primary hyperparathyroidism. Sb. Lek. 90, 200–205. (in Czech)
20. Taylor, W. H., Khaleeli, A. A. (1997) Prevalence of primary hyperparathyroidism in patients with diabetes mellitus. Diabet. Med. 14, 386–389. <https://doi.org/10.1002/(SICI)1096-9136(199705)14:5<386::AID-DIA362>3.0.CO;2-3>
21. Vencovský, J., Broulík, P. (2004) The endocrine system. In: Oxford Textbook of Rheumatology. Isenberg, D. A., Maddison, P. J., Woo, P., Glass, D., Breedveld, F. C., Oxford University Press, Oxford.
front cover

ISSN 1214-6994 (Print) ISSN 2336-2936 (Online)

Archive